Okay, hereS a breakdown of the provided list of citations, focusing on the key topics and potential relevance. I’ll categorize them for clarity.
1. HER2+ Breast Cancer Treatment (Primary Focus)
* DESTINY-Breast05 (Interim Analysis): This is a key study focusing on HER2-positive breast cancer after neoadjuvant (before surgery) therapy.It’s an interim analysis, meaning it’s a look at the data before the study is fully complete. This likely investigates the use of a new treatment in patients who still have evidence of cancer after initial treatment.
* Citation: Ann Oncol. 2025;36(suppl 2):S1556- S1557. Abstract LBA1. doi:10.1016/j.annonc.2025.09.021
* DESTINY-Breast11: This is a phase III trial comparing neoadjuvant trastuzumab deruxtecan (a HER2-targeted drug) alone or followed by standard chemotherapy (paclitaxel, trastuzumab, and pertuzumab). It’s focused on high-risk HER2-positive early breast cancer.
* Citation: Harbeck N, Modi S, Pusztai L, et al; DESTINY-Breast11 Trial Investigators. Ann Oncol. Published online October 21, 2025. doi:10.1016/j.annonc.2025.10.019
* TChP chemotherapy: This is a resource from City of Hope describing the TChP chemotherapy regimen (Trastuzumab, Carboplatin, Herceptin, Paclitaxel) used in HER2-positive breast cancer.
* Citation: City of Hope. November 20, 2025. Accessed January 23, 2026. ttps://www.cityofhope.org/hope-matters-blog/tchp-chemo
2. Cancer Treatment – General/Other Cancers
* Bispecific Antibodies: This article discusses the use of bispecific antibodies in cancer treatment, including new combinations and earlier lines of therapy. Bispecific antibodies are designed too target two different proteins simultaneously,perhaps enhancing their effectiveness.
* Citation: Caffrey M. Am J Manag Care. 2026;32(Spec 01):SP32.
* Multiple Myeloma – Daratumumab Combination: This study (CEPHEUS trial) investigates the use of daratumumab (an antibody targeting a protein on myeloma cells) in combination with standard myeloma treatments (bortezomib, lenalidomide, and dexamethasone) for patients who are not candidates for stem cell transplant.
* Citation: Usmani SZ, Facon T, Hungria V, et al. Nat Med. 2025;31(4):1195-1202. doi:10.1038/s41591-024-03485-7
* Multiple myeloma – Daratumumab Addition to KRd: This study (ADVANCE trial) examines adding daratumumab to the standard krd regimen (carfilzomib, lenalidomide, and dexamethasone) for newly diagnosed multiple myeloma.
* Citation: Landgren CO, Ye JC, Hillengrass J, et al. J Clin Oncol. 2025;43(suppl 16):7503.doi:10.1200/JCO.2025.43.16_suppl.7503
Key Takeaways & Potential Connections:
* focus on HER2+ Breast Cancer: The DESTINY-Breast05 and DESTINY-Breast11 trials are central to understanding advancements in HER2-positive breast cancer treatment, particularly in the neoadjuvant setting.
* New Targeted Therapies: Trastuzumab deruxtecan (DESTINY trials) and bispecific antibodies (Caffrey article) represent newer, more targeted approaches to cancer treatment.
* Combination Therapies: Several studies (CEPHE
